Redox state of human serum albumin as a post-discharge prognostic marker in patients hospitalized for heart failure.

Autor: Nishikawa T; Department of Biomolecular Sciences, Field of Omics Health Sciences, Nagoya University Graduate School, Nagoya, Japan; Department of Rehabilitation, Japan Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan., Ueyama J; Department of Biomolecular Sciences, Field of Omics Health Sciences, Nagoya University Graduate School, Nagoya, Japan., Shimizu S; Department of Cardiology, Kariya Toyota General Hospital, Kariya, Japan., Shibata Y; Department of Cardiology, Japan Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan., Yamada S; Department of Cardiology, Aichi Medical University, Nagakute, Japan. Electronic address: yamadas@aichi-med-u.ac.jp.
Jazyk: angličtina
Zdroj: International journal of cardiology [Int J Cardiol] 2024 Dec 01; Vol. 416, pp. 132497. Date of Electronic Publication: 2024 Aug 28.
DOI: 10.1016/j.ijcard.2024.132497
Abstrakt: Background: Heart failure (HF) is a global health concern, and oxidative stress has been implicated in its progression. The redox state of human serum albumin, a systemic oxidative biomarker, holds promise as a prognostic marker in HF. This study aimed to investigate the association between the fraction of human mercaptalbumin (fHMA), an indicator of human serum albumin's redox state, and adverse events in HF within a prospective single-hospital-based cohort.
Methods: We enrolled patients hospitalized for HF and measured fHMA using high-performance liquid chromatography at discharge. The primary endpoint was the composite of HF rehospitalization and all-cause death within one year after discharge.
Results: A total of 221 participants (median age:79 years; 35 % female) were included in the study. Over the course of one year, 26.1 % of the patients experienced HF readmission, while 13.1 % died. The low fHMA group divided by median of fHMA (<57.6 %) showed higher composite outcome rates (41.4 % for the low fHMA vs. 24.6 % for the high fHMA, p = 0.0114). Multivariate analysis, accounting for seven potential confounders, identified low fHMA (adjusted HR: 1.79 [1.03-3.11]) and lower hemoglobin as independent predictors of HF prognosis.
Conclusions: The findings in this study provide the first evidence that fHMA is a potential novel prognostic biomarker in patients with HF.
Competing Interests: Declaration of competing interest The authors declare that they have no conflicts of interest.
(Copyright © 2024. Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: